Fig. 3: Posterior survival curves and Kaplan–Meier estimates by therapy arm and biomarker signature status (positive versus negative). | Nature Medicine

Fig. 3: Posterior survival curves and Kaplan–Meier estimates by therapy arm and biomarker signature status (positive versus negative).

From: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial

Fig. 3

Posterior survival curves (smooth) and Kaplan–Meier estimates (step function) for the time to NLCB with ARPIs and taxanes. Left: Patients negative for a specific biomarker signature. Right: Patients positive for the respective biomarker signature. Survival curves were estimated using Weibull accelerated failure time survival models with an interaction term, enabling the assessment of differential treatment effects. The smoothed colored lines represent medians of the posterior distribution, while shaded areas depict corresponding 90% CrI. Top: AR (SNV/GSR) positive or TP53 altered versus AR (SNV/GSR) negative and TP53 wild type. Middle: TMPRSS2–ERG fusion negative versus TMPRSS2–ERG positive. Bottom: TP53 wild type versus TP53 altered. Homologous recombination deficiency was left out due to very few randomizations to ARPIs; preliminary results are available in Supplementary Fig. 5 and Table 3.

Back to article page